Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Atezolizumab + Chemotherapy in Resected NSCLC
NCT04367311Phase 2Active, not recruiting
- Sponsor
- Nasser Hanna
- Start
- May 2020
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Nasser Hanna. Started May 2020; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04367311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04367311.